false
0001692415
0001692415
2026-11-13
2026-11-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): November
13, 2026
CO-DIAGNOSTICS,
INC.
(Exact
name of registrant as specified in its charter)
| Utah |
|
1-38148 |
|
46-2609363 |
| (State
or other jurisdiction of |
|
(Commission |
|
(IRS
Employer |
| incorporation
or organization) |
|
File
Number) |
|
Identification
Number) |
2401
S. Foothill Drive, Suite
D, Salt
Lake City, Utah
84109
(Address
of principal executive offices)
(801)
438-1036
(Issuer’s
telephone number)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
| ☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, par value $0.001 per share |
|
CODX |
|
The
Nasdaq Capital
Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
On
November 13, 2026, Co-Diagnostics, Inc. (the “Company”) held a court-ordered special meeting of shareholders (the “Special
Meeting”). At the Special Meeting, the Company’s shareholders approved Amendment No. 1 (the “Plan Amendment”)
to the Co-Diagnostics, Inc. 2025 Equity Incentive Plan (the “Plan”). The Company’s Board of Directors had previously
approved the Plan Amendment, subject to shareholder approval. The Plan Amendment became effective when the shareholders approved it on
November 13, 2026.
The
Plan Amendment increases the number of shares of the Company’s common stock, par value $0.001 per share (“Common Stock”),
authorized for issuance under the Plan by 2,000,000 shares. As amended, the Plan provides that, subject to adjustment as provided in
the Plan, the maximum number of shares of Common Stock that may be issued or transferred under awards granted under the Plan is 2,223,333
shares. To that number are added any shares that become available for issuance under the Plan when awards granted under the Company’s
Amended and Restated 2015 Long-Term Incentive Plan (the “2015 Plan”) are cancelled or forfeited. The Plan Amendment also
sets the maximum number of shares of Common Stock that may be issued on the exercise of incentive stock options granted under the Plan
at 2,223,333 shares, subject to adjustment as provided in the Plan. Apart from the increase in the share reserve, the Plan Amendment
does not materially change the terms of the Plan. The Company’s employees, non-employee directors and consultants, including its
executive officers, are eligible to receive awards under the Plan.
The
material terms of the Plan, as amended by the Plan Amendment, are summarized in the Company’s definitive proxy statement on Schedule
14A for the Special Meeting. That proxy statement was filed with the Securities and Exchange Commission on October 26, 2026 (the “Proxy
Statement”). The summary appears under the caption “Proposal No. 2 — Approval of an Increase in the Number of Shares
Authorized for Issuance Under the Co-Diagnostics, Inc. 2025 Equity Incentive Plan” and is incorporated herein by reference. The
description above and the summary in the Proxy Statement are not complete. They are qualified in their entirety by the full text of the
Plan Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.
The
voting results for the Plan Amendment are reported under Item 5.07 of this Current Report on Form 8-K.
Item
5.07 Submission of Matters to a Vote of Security Holders
On
November 13, 2026, the Company held a Special Meeting of shareholders at which the following matters were voted on:
Proposal
No. 1: Election of Directors. The Company’s shareholders elected for a one-year term each of the persons nominated for election
as a director. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors:
| Nominee |
|
Votes For |
|
Votes Withheld |
|
Broker Non-votes |
| Dwight Egan |
|
1,280,609 |
|
314,073 |
|
2,092,364 |
| Eugene Durenard |
|
1,461,469 |
|
133,213 |
|
2,092,364 |
| Richard Serbin |
|
1,461,461 |
|
133,221 |
|
2,092,364 |
| James Nelson |
|
1,459,292 |
|
135,390 |
|
2,092,364 |
| Edward Murphy |
|
1,447,019 |
|
147,663 |
|
2,092,364 |
There
were no abstentions with respect to the election of directors.
Proposal
No. 2: A proposal to approve an increase in the number of shares of common stock authorized for issuance under the Company’s
Co-Diagnostics, Inc. 2025 Equity Incentive Plan, as described in the Proxy Statement. This proposal was adopted.
| For | |
Against | |
Abstain | |
Broker
Non-votes |
| 1,017,401 | |
571,209 | |
6,072 | |
2,092,364 |
Proposal
No. 3: A proposal to adopt, on an advisory basis, a non-binding resolution approving the compensation of the Company’s named
executive officers, as described in the Proxy Statement under “Executive Compensation.” This proposal was adopted.
| For | |
Against | |
Abstain | |
Broker
Non-votes |
| 1,099,440 | |
486,505 | |
8,737 | |
2,092,364 |
Proposal
No. 4: A proposal to ratify the Audit Committee’s appointment of Tanner LLC as the Company’s independent registered public
accounting firm for the year ending December 31, 2026. This proposal was ratified.
| For | |
Against | |
Abstain | |
Broker
Non-votes |
| 2,908,169 | |
752,419 | |
26,458 | |
- |
Proposal
No. 5: A proposal to approve an amendment to the Company’s Articles of Incorporation to provide that shares representing one-third
of the votes entitled to be cast on a matter shall constitute a quorum for the transaction of business at a meeting of shareholders.
This proposal was approved.
| For |
|
Against |
|
Abstain |
|
Broker Non-votes |
| 1,163,672 |
|
427,187 |
|
3,823 |
|
2,092,364 |
Proposal
No. 6: A proposal to approve the potential exercise of the new warrants to purchase an aggregate of 3,404,724 shares of common stock
at an exercise price of $1.56 per share that were issued on August 3, 2026 pursuant to that certain inducement agreement dated July 30,
2026, for which stockholder approval is required in accordance with Nasdaq Listing Rule 5635(d). This proposal was approved.
| For | |
Against | |
Abstain | |
Broker
Non-votes |
| 1,304,745 | |
284,259 | |
5,516 | |
2,092,364 |
Proposal
No. 7: A proposal to approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of common stock issuable upon conversion
of the secured convertible notes issued in connection with the financing transaction described in the Proxy Statement. This proposal
was approved.
| For |
|
Against | |
Abstain | |
Broker
Non-votes |
| 546,401 |
|
442,538 | |
605,743 | |
2,092,364 |
Proposal
No. 8: A proposal to approve an amendment to the Company’s Articles of Incorporation, as amended, to effect one or more reverse
stock splits of the Company’s issued and outstanding shares of common stock, on one or more occasions, at a ratio of not less than
1-for-2, with the cumulative effect of all such reverse stock splits not to exceed 1-for-750, such final ratio or ratios and the timing
and number of any reverse stock splits to be determined by our Board at any time within twelve months following the Special Meeting,
without further approval or authorization of our stockholders, as described in the Proxy Statement. This proposal was approved.
| For | |
Against | |
Abstain | |
Broker
Non-votes |
| 2,742,151 | |
940,861 | |
4,034 | |
- |
Proposal
No. 9: A proposal to approve any adjournments or postponements of the Special Meeting. This proposal was approved.
| For | |
Against | |
Abstain | |
Broker
Non-votes |
| 3,114,883 | |
549,187 | |
22,976 | |
- |
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
| Exhibit
No. |
|
Description |
| 10.1# |
|
Amendment No. 1 to the Co-Diagnostics, Inc. 2025 Equity Incentive Plan |
| 104 |
|
Cover
Page Interactive Data File (embedded within the Inline XBRL document) |
#
Indicates a management contract or compensatory plan or arrangement.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, hereunto duly authorized.
| |
CO-DIAGNOSTICS,
INC. |
| |
|
|
| Date:
November 13, 2026 |
By: |
/s/
Dwight H. Egan |
| |
Name: |
Dwight
Egan |
| |
Title: |
Chief
Executive Officer
(Principal
Executive Officer) |